Your session is about to expire
← Back to Search
Omega-3 for Loss of Smell
Phase 2
Waitlist Available
Led By Alfred-Marc Iloreta, MD
Research Sponsored by Icahn School of Medicine at Mount Sinai
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, weeks 1, 2, 4 and 6 after softgel initiation
Summary
This trial is testing whether taking omega-3 supplements can help people who have lost their sense of smell due to COVID-19. The study focuses on patients with this specific issue because it affects their quality of life. Omega-3 supplements might help by protecting and repairing the nerves involved in smelling. Omega-3 fatty acids have been shown to enhance immune response, reduce inflammation, and improve symptoms in patients with COVID-19.
Eligible Conditions
- Loss of Smell
- Coronavirus
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, weeks 1, 2, 4 and 6 after softgel initiation
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, weeks 1, 2, 4 and 6 after softgel initiation
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in Brief Smell Identification Test (BSIT)
Change in Brief Smell Identification Test (BSIT) in Participants With Laboratory-Confirmed COVID-19
Change in Brief Smell Identification Test (BSIT) in Participants With Laboratory-Confirmed COVID-19 and Severe Olfactory Dysfunction
+1 moreSecondary study objectives
Modified Brief Questionnaire of Olfactory Dysfunction (mQOD-NS)
Sinonasal Outcomes Test (SNOT-22)
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: Omega-3Active Control1 Intervention
1,000 mg of omega-3 fatty acid (2 softgels per day for 6 weeks)
Group II: Placebo/ControlPlacebo Group1 Intervention
2 softgels per day for 6 weeks
Find a Location
Who is running the clinical trial?
Icahn School of Medicine at Mount SinaiLead Sponsor
903 Previous Clinical Trials
541,628 Total Patients Enrolled
Alfred-Marc Iloreta, MD4.918 ReviewsPrincipal Investigator - Icahn School of Medicine at Mount Sinai
The Mount Sinai Hospital, The New York Eye and Ear Infirmary, Mount Sinai West
Medical School - University of Kansas, Doctor of Medicine
Mount Sinai Hospital, Residency in Otolaryngology
2 Previous Clinical Trials
83 Total Patients Enrolled
3Patient Review
The wait for medication was far too long — nearly three days. And even now, trying to get in touch with them has been difficult.
Share this study with friends
Copy Link
Messenger